AstraZeneca has doubled down on plans to grow its US business as it braces for the country’s potential tariffs on the pharmaceutical industry. The drug maker said it is "firmly committed to investing ...

The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of ...

LONDON (Reuters) -The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance ...

The US FDA has granted breakthrough device designation to Roche's companion diagnostic VENTANA TROP2 (EPR20043) RxDx Device.

AstraZeneca CEO Pascal Soriot discusses earnings, the potential trade tariff impact on the business and the outlook for the ...

On a per-share basis, the Cambridge, Britain-based company said it had profit of 93 cents. Earnings, adjusted for non-recurring costs, came to $1.24 per share. The results topped Wall Street ...

Pharmaceutical giant AstraZeneca is making "excellent progress" toward its ambition of hitting $80bn in revenue by 2030, following a strong first quarter.

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

The head of Britain’s largest drug company has demanded Europe ramp up spending on medicines amid fears over Donald Trump’s ...

Europe is putting its "ability to protect the health of its own people at risk", the CEO of FTSE 100 giant Astrazeneca has ...

AstraZeneca's Enhertu shows significant success in late-stage trials as a first-line treatment for HER2-positive metastatic ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best UK stocks to invest in. Like most of the world, the United Kingdom is also facing ...